REV-ERB agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-07. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
== Synthesis == Fumaric acid is produced based on catalytic isomerisation of maleic acid in aqueous solutions at low pH. It precipitates from the reaction solution. Maleic acid is accessible in large volumes as a hydrolysis product of maleic anhydride, produced by catalytic oxidation of benzene or butane.
== H == habitat – HACEK organism – halobacteria – haploid – Hardy–Weinberg principle – heart – Hela cell – helper T cell – Hepadnaviridae – hepatitis B – herbivore – heredity – hereditary disease – hermaphrodite – herpetology – Hershey–Chase experiment – heterochromatin – heterotroph – heterozygote – Hfr cell – hibernation – hierarchy of life – Hill reaction – His tag – histone – homeobox – homeostasis – homologous recombination – homology – homoplasy – homozygote – homunculus – horizontal gene transfer – hormone – host – household gene – human – Human Genome Project – humoral immunity – hybrid (biology) – hybridization – hydrolysis – hydrolytic enzyme – hygiene – hyperpolarization (biology)
== Sterilization of Women Living With HIV in Latin America == Forced and coerced sterilization of Latina women is not limited to the United States; it is an internationally recognized human rights violation. In Latin America, women living with HIV have reported being pressured or coerced into sterilization by healthcare providers. A 2015 study by Kendall and Albert conducted qualitative analysis of reports of how and when healthcare providers pressured women living with HIV in Latin America to be sterilized. They also assessed whether social, economic or fertility history characteristics were associated with the pressure to sterilize. Researchers found that approximately 23% of the women living with HIV reported experiencing pressure to undergo sterilization after their diagnosis. Those who were pregnant while both themselves and their healthcare providers were aware of their HIV status were nearly six times more likely to face coerced or forced sterilization compared to those who were not pregnant with a known diagnosis. Participants reported that some healthcare providers suggested an HIV diagnosis limited their ability to make decisions about having children or choosing contraception. In some cases, physicians were reported to have provided misleading information about related pregnancy risks or withheld services intended to prevent mother-to-child HIV transmission in order to pressure women into sterilization. Reports also indicated that forced sterilizations sometimes occurred during caesarean deliveries.
Sources: en.wikipedia.org
MALDI/TOF serves as a method for determining the drug resistance of bacteria, especially to β-lactams (Penicillin family). The MALDI/TOF detects the presence of carbapenemases, which indicates drug resistance to standard antibiotics. It is predicted that this could serve as a method for identifying a bacterium as drug resistant in as little as three hours. This technique could help physicians decide whether to prescribe more aggressive antibiotics initially.
In August 2025, Moore's chief of staff, Fagan Harris, announced that he would resign his post at the end of the year to become the next president of the Abell Foundation; he was succeeded by Lester Davis, a CareFirst BlueCross BlueShield executive who worked as an unpaid outside advisor to Moore's 2022 gubernatorial campaign. In October 2025, Roland Butler resigned as secretary of state police and was succeeded by state senator Michael A. Jackson. In November 2025, Paul Monteiro resigned as secretary of Maryland Department of Service and Civic Innovation and was succeeded by Jonny Dorsey, one of Moore's deputy chiefs of staff. In October 2025, Moore appointed Walter Simmons to serve as the secretary of the newly created Department of Social and Economic Mobility. Two of Moore's cabinet secretaries resigned in 2026. Maryland Secretary of Human Services Rafael López, who resigned on February 23, citing health reasons, and was succeeded by deputy secretary Gloria Brown Burnett, who will serve as acting secretary until April 1, when Stacy Rodgers will then take over as acting secretary. In March 2026, Rai announced that he would step down on March 27, and would be succeeded by deputy secretary Elena Quiroz-Livanis, who will serve as acting secretary until a search for a new, permanent secretary is completed.
===== Clinical Laboratory Building ===== UPMC's nine-story Clinical Laboratory Building (CLB) opened in 2013 and cost $39 million. The CLB is located in the Oakland neighborhood and is situated between Magee-Womens Hospital and UPMC Presbyterian Hospital. Much of UPMC's laboratory testing is performed within the CLB. An extensive pneumatic tube system connects the CLB with UPMC hospitals that are in the Oakland neighborhood (Presbyterian, Magee-Womens, Montefiore) to facilitate the transport of specimens from the hospitals to the laboratories.
Sources: en.wikipedia.org
=== Secondary Sources === Blackmore, Tim (2010), "Save Now [Y/N]? Machine Memory at War in Iain M. Banks' Look to Windward", Bulletin of Science, Technology & Society, 30 (4): 259–273, doi:10.1177/0270467610373816, ISSN 0270-4676, S2CID 144415805 Brown, Chris (2001), "'Special Circumstances': Intervention by a Liberal Utopia", Millennium – Journal of International Studies, 30 (3): 625–626, doi:10.1177/03058298010300031601, S2CID 143328512. Horwich, David (21 January 2002), "Culture Clash: Ambivalent Heroes and the Ambiguous Utopia in the Work of Iain M. Banks", Strange Horizons, retrieved 3 August 2021. Jackson, Patrick Thaddeus; Heilman, James (2008), "Outside Context Problems: Liberalism and the Other in the Work of Iain M.Banks", in Hassler, D.M.; Wilcox, C. (eds.), New Boundaries in Political Science Fiction, University of South Carolina Press, pp. 235–258, ISBN 978-1-57003-736-8, retrieved 9 December 2008. Lippens, Ronnie (2002), "Imachinations of Peace: Scientifictions of Peace in Iain M. Banks's The Player of Games", Utopian Studies, 13 (1): 135–147, ISSN 1045-991X, OCLC 5542757341. Newitz, Annalee (2019), The future of another timeline, Little, Brown Book Group Limited, ISBN 978-0-356-51123-8, OCLC 1059268855. Norman, Joseph S. (2021), The Culture of "The Culture": Utopian Processes in Iain M. Banks's Space Opera Series, Oxford University Press, ISBN 978-1-78962-174-7, OCLC 1120943463. Rumpala, Yannick (2012), "Artificial intelligences and political organization: An exploration based on the science fiction work of Iain M.
=== Etymology === The Komodo dragon is also sometimes known as the Komodo monitor or the Komodo Island monitor in scientific literature, although these names are uncommon. To the natives of Komodo Island, it is referred to as ora, buaya darat ('land crocodile'), or biawak raksasa ('giant monitor').
=== Detection of cosmic particles === HiSPARC, a Dutch university research Institute, is proposing to challenge teams of secondary school pupils and teachers with the study of ultra-high energy cosmic rays. HiSPARC wants to make young people discover and "experience the sciences" by creating a teaching network of teams of pupil-researchers. Liaising closely with academic and scientific institutions, these groups will work on the design, control and operation of particular items of detection equipment. The retrieval of the data obtained and its analysis will then be the subject of interpretation.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.